Viridian Wins FDA Approval for Lumvoa in Thyroid Eye Disease
WALTHAM, Mass., June 26, 2026 Viridian Therapeutics announced that the U.S. Food and Drug Administration (FDA) has approved Lumvoa™...
IGF-1R
Advertisement
Innovent Highlights Bispecific Antibody Pipeline at ATS and ARVO 2026
SAN FRANCISCO and SUZHOU, China, May 18, 2026 Innovent Biologics presented new clinical and preclinical data from its next-generation...
Viridian Therapeutics Reports Positive REVEAL-2 Results
WALTHAM, Mass., United States – May 5, 2026 Viridian Therapeutics Inc. has announced positive topline results from its Phase...
Amgen TEPEZZA Subcutaneous Trial Shows Strong Phase 3 Results
Thousand Oaks, California, USA, April 6, 2026 Phase 3 Success Expands TEPEZZA Treatment Options In a major advancement for...
Advertisement
